A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection | American Society of Nephrology
Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma - ScienceDirect
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma | NEJM
Results of prospective clinical trials on the use of bortezomib as a... | Download Table
How Effective is VELCADE® (bortezomib)?
VisualAbstract CASTOR trial follow-up: Health-related quality of life was maintained in patients treated with daratumumab, bortezomib, and dexamethasone over time for relapsed or refractory multiple myeloma | 2 Minute Medicine
Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma - Clinical Lymphoma, Myeloma and Leukemia
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial - The Lancet Oncology
Novel Agents for the Treatment of Multiple Myeloma: Proteasome Inhibitors and Immunomodulatory Agents (Open) - JADPRO
How to Treat High-Risk Myeloma at Diagnosis and Relapse | American Society of Clinical Oncology Educational Book
Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes | TCRM
Clinical trials of single-agent bortezomib | Download Table
![Top 10 Velcade Clinical Trials [2022 Studies] | Power](https://pwr-og-img.withpower.com/Apply%20to%20this%20Phase%202%20clinical%20trial%20treating%20Haematological%20Malignancies,%20Hematologic%20Neoplasms:%0A%0ABortezomib%20for%20Hematologic%20Neoplasms.png?md=1 "Top 10 Velcade Clinical Trials [2022 Studies] | Power")
Top 10 Velcade Clinical Trials [2022 Studies] | Power
Frontiers | Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial | BMJ Open
Results of prospective clinical trials on the use of bortezomib as a... | Download Table
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study - Clinical Lymphoma, Myeloma and Leukemia
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial - ScienceDirect
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial - The Lancet
Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies | Nature Reviews Clinical Oncology
Bortezomib in multiple myeloma: treatment approach and outcomes - ScienceDirect
Levine Cancer Institute Myeloma Trials
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma | NEJM
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma | NEJM
